Month: June 2020

TORONTO, June 15, 2020 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly” or the “Company”), a consumer packaged goods company in the cannabis products market, is pleased to announce that its joint venture partner, Sunens Farms Inc. (“Sunens”), has secured a standard cultivation licence from Health Canada for the first phase of its fully automated, purpose-built, 1.1 million sq. ft. greenhouse facility in Leamington, Ontario. The Sunens facility is operational and the team will immediately begin cultivating high-quality organic cannabis within the licensed area. This standard cultivation licence allows Sunens to commence bulk sales of cannabis following harvest without additional regulatory approvals.  Sunens has secured a large and diverse genetic library consisting of over 200 unique strains....

CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the filing of an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) to begin a Phase 1/2a clinical study of GEN-011 in a range of tumor types, with a focus on patients who have failed standard-of-care checkpoint inhibitor therapy. The GEN-011 trial will evaluate patient safety, T cell proliferation and persistence, and clinical activity, with preliminary data expected mid-2021.Powered by ATLAS™, GEN-011 offers several advantages over TIL therapies, the gold standard for solid tumor adoptive cell therapy. Unlike TILs, GEN-011 does not require extra surgery or collection of viable tumor samples and uses...

HOUSTON, June 15, 2020 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for BPX-603. BPX-603 is a GoCAR-T® product candidate targeting solid tumors that express human epidermal growth factor receptor 2 (HER2). BPX-603 is the company’s first dual-switch GoCAR-T® product candidate, which incorporates both the company’s iMC activation and CaspaCIDe® safety switch technologies.“The FDA’s clearance of our IND for BPX-603 marks a significant milestone for Bellicum, adding a second clinical program to further evaluate our novel GoCAR-T technology’s ability to enhance CAR-T and host immune cell activity against solid tumors,”...

NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the United States Department of Defense (DoD), via the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), has increased research and development funding to approximately $23 million in connection with the DoD contract to support work necessary to gain a potential label expansion from the U.S. Food and Drug Administration (FDA) for TPOXX® (tecovirimat) for Post-Exposure Prophylaxis (PEP) in addition to the current approved labeling for the treatment of smallpox. The use of TPOXX for PEP...

TORONTO, June 15, 2020 (GLOBE NEWSWIRE) — Compass Gold Corp. (TSX-V: CVB) (Compass or the Company) is pleased to provide an update on the recently completed drilling at the Tarabala prospect, located on the Company’s Sikasso Property in Southern Mali (Figure 1).HighlightsCoordinated exploration work at Tarabala identifies a pronounced, broad, shallow gold target, associated with a shear zone, extending more than 2-kilometresAir core drilling (24 AC holes, 1,253 m) intersected gold mineralization within the 10 km long Tarabala soil geochemistry trendBest interval was 14 m at 1.24 g/t Au (from 23 m), including 1 m @ 12.99 g/t Au (from 33m)Further geophysical testing planned on other Tarabala Trend prospects in preparation for additional drilling once ground conditions permitCompass CEO, Larry Phillips, said, “Our technical team has...

NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) — Medley Capital Corporation (NYSE: MCC) (TASE: MCC) (the “Company”) announced today that, on June 12, 2020, the board of directors of the Company (the “Board”), including its special committee (the “Special Committee”), has approved an expense support agreement (the “Expense Support Agreement”) under which MCC Advisors LLC and Medley LLC agreed (jointly and severally) to cap the management fee and all of the Company’s other operating expenses (except interest expenses, certain extraordinary strategic transaction expenses, and other expenses approved by the Special Committee at $667,000 per month (the “Cap”).  The Cap is expected to result in a material reduction in the Company’s expenses.  Under the Expense Support Agreement, the Cap will be in effect from June 1, 2020 through September 30,...

RADNOR, Pa., June 15, 2020 (GLOBE NEWSWIRE) — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat orphan seizure disorders, today announced that Martha Manning, Esq., has been appointed Vice President, General Counsel and Secretary.“We are thrilled to welcome Martha to our growing team at Marinus, and believe her legal experience supporting biopharma companies across all development stages will be instrumental as we navigate through our upcoming milestones for ganaxolone in orphan seizure disorders,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus. “Martha will bring invaluable industry leadership to our organization as we begin to plan for and execute potential commercialization, strategic alliances and value enhancing portfolio...

Orlando, Florida, June 15, 2020 (GLOBE NEWSWIRE) — IZEA Worldwide, Inc. (NASDAQ: IZEA), the premier provider of influencer marketing technology, data, and services for the world’s leading brands, announced today that it will be fully restoring employees’ salaries to their pre-COVID levels beginning July 1, 2020. The company had previously announced, via Form 8-K filed on April 23rd, reductions of 19-21% for all employees, including management, and also reduced pay for the company’s Board of Directors. “The entire IZEA team has been working diligently to overcome the global crisis brought on by COVID-19,” said Ted Murphy, Founder and CEO of IZEA. “I want to thank them for their commitment and willingness to make personal sacrifices for the good of the company and our shareholders. This team is truly dedicated to our mission and I...

Company Announcement No. 8/2020Copenhagen, 15 June 2020Attachment2008_Monthly update_May_2020_15_06_2020_UK